文献速递神经眼科小儿眼科与斜弱视

儿童视神经炎6个月视力预后评估

Assessment of Pediatric Optic Neuritis Visual Acuity Outcomes at 6 Months.
PubMed 文献 · JAMA Ophthalmol · 2020-01-01

这项非随机队列研究在美加23个中心前瞻性纳入44例首次发作视神经炎儿童(3-15岁),随访6个月。基线平均高对比度视力0.95 logMAR(20/200),6个月改善0.76 logMAR至0.12 logMAR(20/25);低对比度视力从1.49 logMAR改善0.72 logMAR至0.73 logMAR。研究网络未达到2年招募100例的目标,提示未来治疗试验需调整入选标准或延长招募期。

要点

  • 儿童视神经炎虽基线视力差,但6个月时多数显著改善。
  • 52%患儿MRI显示白质病变,常见相关自身免疫诊断。
  • 研究招募未达目标,提示该病罕见影响试验设计。

核心结论

  • 尽管基线视力差,多数儿童视神经炎患者6个月时视力显著改善。
  • 相关神经系统自身免疫诊断常见,包括MOGAD、ADEM、MS和NMO。
  • 研究网络未达到2年招募100例的目标,提示未来治疗试验需调整设计。

研究设计与样本

  • 非随机队列研究,2016年9月20日至2018年7月20日在美加23个中心开展。
  • 纳入44例3-15岁首次发作视神经炎儿童,症状出现2周内入组。
  • 排除既存眼部异常或既往视神经炎发作的患儿。

主要发现

  • 44例患儿中16例(36%)为双侧视神经炎。
  • MRI显示23例(52%)有白质病变,其中8例MOGAD(18%)、7例ADEM(16%)、5例MS(11%)、3例NMO(7%)。
  • 基线平均HCVA为0.95 logMAR(20/200),6个月改善0.76 logMAR(95%CI 0.54-0.99)至0.12 logMAR(20/25)。
  • 基线平均低对比度视力1.49 logMAR(20/640),6个月改善0.72 logMAR(95%CI 0.54-0.89)至0.73 logMAR(20/100)。
  • 基线HCVA在年龄<10岁、有相关神经自身免疫诊断、白质病变及非白人非西班牙裔种族中更差。

关键数值与推荐

  • 视力纳入标准:受影响眼高对比度视力较年龄 norms 低至少0.2 logMAR,或色觉减退、视野异常、视盘水肿。

临床怎么用

  • 这些发现可用于向家庭咨询疾病预后,多数患儿6个月视力显著改善。
  • 临床应关注相关神经系统自身免疫诊断的筛查。

局限性

  • 研究未达到计划样本量,可能影响结果的代表性。
  • 数据未显示基线因素与HCVA改善之间有统计学显著关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Optic neuritis (ON) in children is uncommon. There are limited prospective data for visual acuity (VA) outcomes, associated diseases, and neuroimaging findings. Prospective data from a large sample would be useful for counseling families on treatment decisions and prognosis. OBJECTIVE: To prospectively study children with a first episode of ON, describe VA after 6 months, and ascertain the network's (Pediatric Eye Disease Investigator Group and Neuro-Ophthalmology Research Disease Investigator Consortium) ability to enroll pediatric patients with ON prospectively. DESIGN, SETTING, AND PARTICIPANTS: This nonrandomized cohort study was conducted from September 20, 2016, to July 20, 2018, at 23 sites in the United States and Canada in pediatric ophthalmology or neuro-ophthalmology clinics. A total of 44 children (aged 3-15 years) presented with a first episode of ON (visual loss, pain on eye movements, or both) within 2 weeks of symptom onset and at least 1 of the following in the affected eye: a distance high-contrast VA (HCVA) deficit of at least 0.2 logMAR below age-based norms, diminished color vision, abnormal visual field, or optic disc swelling. Exclusion criteria included preexisting ocular abnormalities or a previous episode of ON. MAIN OUTCOMES AND MEASURES: Primary outcomes were monocular HCVA and low-contrast VA at 6 months. Secondary outcomes were neuroimaging, associated diagnoses, and antibodies for neuromyelitis optica and myelin oligodendrocyte glycoprotein. RESULTS: A total of 44 children (mean age [SD], 10.2 [3.5] years; 26 boys [59%]; 23 White individuals [52%]; 54 eyes) were enrolled in the study. Sixteen patients (36%) had bilateral ON. Magnetic resonance imaging revealed white matter lesions in 23 children (52%). Of these children, 8 had myelin oligodendrocyte glycoprotein-associated demyelination (18%), 7 had acute disseminated encephalomyelitis (16%), 5 had multiple sclerosis (11%), and 3 had neuromyelitis optica (7%). The baseline mean HCVA was 0.95 logMAR (20/200), which improved by a mean 0.76 logMAR (95% CI, 0.54-0.99; range, -0.70 to 1.80) to 0.12 logMAR (20/25) at 6 months. The baseline mean distance low-contrast VA was 1.49 logMAR (20/640) and improved by a mean 0.72 logMAR (95% CI, 0.54-0.89; range, -0.20 to 1.50) to 0.73 logMAR (20/100) at 6 months. Baseline HCVA was worse in younger participants (aged <10 years) with associated neurologic autoimmune diagnoses, white matter lesions, and in those of non-White race and non-Hispanic ethnicity. The data did not suggest a statistically significant association between baseline factors and improvement in HCVA. CONCLUSIONS AND RELEVANCE: The study network did not reach its targeted enrollment of 100 pediatric patients with ON over 2 years. This indicates that future treatment trials may need to use different inclusion criteria or plan a longer enrollment period to account for the rarity of the disease. Despite poor VA at presentation, most children had marked improvement by 6 months. Associated neurologic autoimmune diagnoses were common. These findings can be used to counsel families about the disease.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Pineles SL, Repka MX, Liu GT, et al. Assessment of Pediatric Optic Neuritis Visual Acuity Outcomes at 6 Months. JAMA Ophthalmol. 2020. PMID: 33057592. doi:10.1001/jamaophthalmol.2020.4231

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。